Foxhollow Technologies Inc.
Medical Devices & Tech
740 Bay Road
Redwood City, CA 94063 USA
phone: 888-SLVR-HWK
fax: 888.233.2849
Symbol FOXH
Exchange Nasdaq
Founded 1996
Employees 246
www.foxhollowtech.com
Research Sector Medical Devices & Tech
Summary Description
Treatment of peripheral and coronary arterial disease.
Management
John B. Simpson, PhD., M.D., Chief Executive Officer and Founder; Ronald T. Steckel, Chief Operating Officer; Matt Ferguson, Chief Financial Officer; Duke Rohlen, President of Strategic Operations; Daniel J. Lerner, M.D., Senior Vice President of Molecular Programs; Suzon Lommel, Vice President of Quality and Regulatory Affairs; Bill Olson, Vice President of Corporate Development; Angela Soito, Senior Vice President of Clinical Affairs; Ron Songer, Senior Vice President of Research and Development; Robert Wood, Senior Vice President of Operations and Quality; Richard Zimmer, Senior Vice President of US Sales
Ownership
Financials


* numbers in thousands

 
Keywords
peripheral, coronary arterial disease, heart, plaques, blood,

Comment | Printable Version | Nov. 01, 2008
If you work for Foxhollow Technologies Inc. and want to update this profile, click here

Description
Foxhollow Technologies, Inc. engages in the design, development, manufacture, and sale of medical devices primarily for the treatment of peripheral artery disease
Products / Services
The company sells the SilverHawk Plaque Excision System, a minimally-invasive single-use catheter system designed for removal of plaque from arteries
Market / Customers
It markets its product through its direct sales force in the United States primarily to interventional cardiologists, as well as to vascular surgeons and interventional radiologists.
Competitors / Substitutes / Alternatives
BSX = Boston Scientific Corp. MDT = Medtronic Inc. Industry = Medical Instruments & Supplies
Strategy
FoxHollow is collecting both clinical outcomes data and tissue specimens, which may help enable the identification of predictive markers for restenosis, elevated cardiovascular risk and other conditions. Finding these markers may pave the way to the companys ultimate goalunderstanding and eventually eradicating vascular disease.


2008-11-22-567